Literature DB >> 21198669

Immunology of gut mucosal vaccines.

Marcela F Pasetti1, Jakub K Simon, Marcelo B Sztein, Myron M Levine.   

Abstract

Understanding the mechanisms underlying the induction of immunity in the gastrointestinal mucosa following oral immunization and the cross-talk between mucosal and systemic immunity should expedite the development of vaccines to diminish the global burden caused by enteric pathogens. Identifying an immunological correlate of protection in the course of field trials of efficacy, animal models (when available), or human challenge studies is also invaluable. In industrialized country populations, live attenuated vaccines (e.g. polio, typhoid, and rotavirus) mimic natural infection and generate robust protective immune responses. In contrast, a major challenge is to understand and overcome the barriers responsible for the diminished immunogenicity and efficacy of the same enteric vaccines in underprivileged populations in developing countries. Success in developing vaccines against some enteric pathogens has heretofore been elusive (e.g. Shigella). Different types of oral vaccines can selectively or inclusively elicit mucosal secretory immunoglobulin A and serum immunoglobulin G antibodies and a variety of cell-mediated immune responses. Areas of research that require acceleration include interaction between the gut innate immune system and the stimulation of adaptive immunity, development of safe yet effective mucosal adjuvants, better understanding of homing to the mucosa of immunologically relevant cells, and elicitation of mucosal immunologic memory. This review dissects the immune responses elicited in humans by enteric vaccines.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21198669      PMCID: PMC3298192          DOI: 10.1111/j.1600-065X.2010.00970.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  241 in total

1.  Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.

Authors:  Samer S El-Kamary; Marcela F Pasetti; Paul M Mendelman; Sharon E Frey; David I Bernstein; John J Treanor; Jennifer Ferreira; Wilbur H Chen; Richard Sublett; Charles Richardson; Robert F Bargatze; Marcelo B Sztein; Carol O Tacket
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

Review 2.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

3.  Immunological studies in typhoid fever. II. Cell-mediated immune responses and lymphocyte subpopulations in patients with typhoid fever.

Authors:  P Rajagopalan; R Kumar; A N Malaviya
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

4.  A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results.

Authors:  M H Wahdan; C Sérié; Y Cerisier; S Sallam; R Germanier
Journal:  J Infect Dis       Date:  1982-03       Impact factor: 5.226

5.  Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.

Authors:  George E Armah; Samba O Sow; Robert F Breiman; Michael J Dallas; Milagritos D Tapia; Daniel R Feikin; Fred N Binka; A Duncan Steele; Kayla F Laserson; Nana A Ansah; Myron M Levine; Kristen Lewis; Michele L Coia; Margaret Attah-Poku; Joel Ojwando; Stephen B Rivers; John C Victor; Geoffrey Nyambane; Abraham Hodgson; Florian Schödel; Max Ciarlet; Kathleen M Neuzil
Journal:  Lancet       Date:  2010-08-06       Impact factor: 79.321

6.  Ex Vivo kinetics of early and long-term multifunctional human leukocyte antigen E-specific CD8+ cells in volunteers immunized with the Ty21a typhoid vaccine.

Authors:  Rosângela Salerno-Goncalves; Rezwanul Wahid; Marcelo B Sztein
Journal:  Clin Vaccine Immunol       Date:  2010-07-21

7.  Reactogenicity, immunogenicity and efficacy studies of Escherichia coli type 1 somatic pili parenteral vaccine in man.

Authors:  M M Levine; R E Black; C C Brinton; M L Clements; P Fusco; T P Hughes; S O'Donnell; R Robins-Browne; S Wood; C R Young
Journal:  Scand J Infect Dis Suppl       Date:  1982

8.  Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance.

Authors:  A Z Kapikian; R G Wyatt; M M Levine; R H Yolken; D H VanKirk; R Dolin; H B Greenberg; R M Chanock
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

9.  Vi serology in detection of chronic Salmonella typhi carriers in an endemic area.

Authors:  C F Lanata; M M Levine; C Ristori; R E Black; L Jimenez; M Salcedo; J Garcia; V Sotomayor
Journal:  Lancet       Date:  1983-08-20       Impact factor: 79.321

10.  Immunogenicity of Ty21a attenuated "Salmonella typhi" given with sodium bicarbonate or in enteric-coated capsules.

Authors:  R Black; M M Levine; C Young; J Rooney; S Levine; M L Clements; S O'Donnell; T Hugues; R Germanier
Journal:  Dev Biol Stand       Date:  1983
View more
  89 in total

1.  Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity.

Authors:  Qingke Kong; David A Six; Kenneth L Roland; Qing Liu; Lillian Gu; C Michael Reynolds; Xiaoyuan Wang; Christian R H Raetz; Roy Curtiss
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

2.  Transcription factor Batf3 is important for development of CD8+ T-cell response against a phagosomal bacterium regardless of the location of antigen.

Authors:  Rajen Patel; Subash Sad
Journal:  Immunol Cell Biol       Date:  2015-12-08       Impact factor: 5.126

Review 3.  Vaccination against Salmonella Infection: the Mucosal Way.

Authors:  Rémi Gayet; Gilles Bioley; Nicolas Rochereau; Stéphane Paul; Blaise Corthésy
Journal:  Microbiol Mol Biol Rev       Date:  2017-06-14       Impact factor: 11.056

Review 4.  Live attenuated vaccines for invasive Salmonella infections.

Authors:  Sharon M Tennant; Myron M Levine
Journal:  Vaccine       Date:  2015-04-19       Impact factor: 3.641

Review 5.  Plant-made oral vaccines against human infectious diseases-Are we there yet?

Authors:  Hui-Ting Chan; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2015-09-07       Impact factor: 9.803

6.  An attenuated Listeria monocytogenes vector primes more potent simian immunodeficiency virus-specific mucosal immunity than DNA vaccines in mice.

Authors:  Eung-Jun Im; Erica N Borducchi; Nicholas M Provine; Anna G McNally; Sufen Li; Fred R Frankel; Dan H Barouch
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

Review 7.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

8.  Timing of Birth as an Emergent Risk Factor for Rotavirus Hospitalization and Vaccine Performance in the Postvaccination Era in the United States.

Authors:  Benjamin Lopman; Rebecca Dahl; Minesh Shah; Umesh D Parashar
Journal:  Am J Epidemiol       Date:  2018-08-01       Impact factor: 4.897

9.  Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine.

Authors:  Guangyu Zhao; Yu Miao; Yan Guo; Hongjie Qiu; Shihui Sun; Zhihua Kou; Hong Yu; Junfeng Li; Yue Chen; Shibo Jiang; Lanying Du; Yusen Zhou
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Circulating Gut-Homing (α4β7+) Plasmablast Responses against Shigella Surface Protein Antigens among Hospitalized Patients with Diarrhea.

Authors:  Anuradha Sinha; Ayan Dey; Giulietta Saletti; Pradip Samanta; Partha Sarathi Chakraborty; M K Bhattacharya; Santanu Ghosh; T Ramamurthy; Jae-Ouk Kim; Jae Seung Yang; Dong Wook Kim; Cecil Czerkinsky; Ranjan K Nandy
Journal:  Clin Vaccine Immunol       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.